Kringle Pharma, Inc. (4884.T)
JPY 814.0
(-0.73%)
JPY 814.0
(-0.73%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 596.95 Million JPY | 42.3% |
| 2022 | 419.5 Million JPY | 224.0% |
| 2021 | 129.47 Million JPY | -19.94% |
| 2020 | 161.72 Million JPY | 355.89% |
| 2019 | 35.47 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 483.21 Million JPY | -19.05% |
| 2024 Q3 | 600.79 Million JPY | 1.87% |
| 2024 Q2 | 589.75 Million JPY | 22.05% |
| 2023 FY | 596.95 Million JPY | 42.3% |
| 2023 Q1 | 158 Million JPY | -62.34% |
| 2023 Q2 | 391.07 Million JPY | 147.52% |
| 2023 Q4 | 596.95 Million JPY | -2.87% |
| 2023 Q3 | 614.61 Million JPY | 57.16% |
| 2022 Q4 | 419.5 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 81.615% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -841.406% |
| GNI Group Ltd. | 26.34 Billion JPY | 97.734% |
| Linical Co., Ltd. | 10.3 Billion JPY | 94.207% |
| Trans Genic Inc. | 3.81 Billion JPY | 84.342% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -1.144% |
| Soiken Holdings Inc. | 697.02 Million JPY | 14.356% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 80.238% |
| AnGes, Inc. | 2.78 Billion JPY | 78.599% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -16.228% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.34% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -68.979% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 63.818% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -26.378% |
| CanBas Co., Ltd. | 91.98 Million JPY | -548.949% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 45.414% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 26.286% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -0.543% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 85.967% |
| PeptiDream Inc. | 29.11 Billion JPY | 97.95% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -5.376% |
| Ribomic Inc. | 155.8 Million JPY | -283.133% |
| SanBio Company Limited | 2.25 Billion JPY | 73.526% |
| Healios K.K. | 11.28 Billion JPY | 94.711% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -137.576% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -61.776% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -147.189% |
| StemRIM | 187 Million JPY | -219.227% |
| CellSource Co., Ltd. | 677.73 Million JPY | 11.92% |
| FunPep Company Limited | 189.32 Million JPY | -215.309% |
| Stella Pharma Corporation | 1.44 Billion JPY | 58.648% |
| TMS Co., Ltd. | 97.68 Million JPY | -511.077% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -552.453% |
| Cuorips Inc. | 200.96 Million JPY | -197.05% |
| K Pharma,Inc. | 209.13 Million JPY | -185.441% |
| Takara Bio Inc. | 11.42 Billion JPY | 94.773% |
| ReproCELL Incorporated | 741.03 Million JPY | 19.443% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 34.952% |
| StemCell Institute Inc. | 3.85 Billion JPY | 84.497% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 34.287% |
| CellSeed Inc. | 301.04 Million JPY | -98.293% |